San Mateo, CA, United States
San Mateo, CA, United States

Time filter

Source Type

News Article | May 29, 2017
Site: www.prnewswire.com

IBS-D ist eine multifaktorielle, symptombasierte Störung, die durch wiederholt auftretende Abdominalschmerzen oder -beschwerden und veränderte Darmfunktion gekennzeichnet ist. Sie beeinträchtigt zwischen 10 bis 20 Prozent der Menschen in der entwickelten Welt, wobei ein Drittel von ihnen mit Durchfall assoziiertes IBS hat. IBS-D kommt mehr bei Frauen als bei Männern vor (14 % vs. 9 %). Ungefähr 57 % der Patienten leiden täglich unter Symptomen, 25 % wöchentlich und 14 % monatlich. Die Krankheit wirkt sich auf das tägliche Leben, die Arbeit und die Freizeit aus. Die Kosten der medizinischen Versorgung von IBS-Patienten sind ungefähr 40 % höher als für die Bevölkerung im Allgemeinen. IBS-Patienten machen ungefähr 20 % der sekundären ambulanten Pflegebürde eines Arztes für Magen-Darm-Erkrankungen aus. Die US-amerikanische Lebens- und Arzneimittelbehörde FDA hat vor Kurzem erklärt, dass ein großer Bedarf an neuen Behandlungen für IBS besteht. OrphoMed ist ein in der Region San Francisco Bay basiertes, auf der klinischen Stufe aktives Biopharma-Unternehmen, das sich auf die Entwicklung von neuen erstklassigen Dimerkonjugaten mit überlegenen  therapeutischen Profilen konzentriert. Das Unternehmen setzt seine proprietäre Dimerplattformtechnologie ein, um die Probleme der viszeralen Hypersensitivität und Hypermotilität in funktionell gastrointestinalen Erkrankungen zu beheben. Die Dimere von OrphoMed sind durch Patente bzgl. der Zusammensetzung des Materials und der Verwendungsmethode geschützt. OrphoMed erkundet auch therapeutische Anwendungen und Partnerschaftsgelegenheiten für andere Dimerkonjugate, die sich in seiner Pipeline befinden. Weitere Information finden Sie unter New Enterprise Associates, Inc. (NEA) ist eine weltweite Risikokapitalgesellschaft, die sich darauf konzentriert, jungen Unternehmern beim Aufbau von transformierenden Unternehmen über viele Phasen, Sektoren und Geografien hinweg zu helfen. Mit mehr als 19 Mrd. USD an insgesamt seit der Gründung des Unternehmens im Jahre 1977 gebundenem Kapital investiert NEA in Technologie- und Gesundheitswesensunternehmen in allen Stadien im Lebenszyklus eines Unternehmens, von der Seed-Phase bis hin zum IPO. Die lange Erfolgsbilanz des Unternehmens hinsichtlich erfolgreichem Anlegen umfasst IPOs von mehr als 210 Portfolio-Unternehmen und mehr als 360 Akquisitionen. Weitere Informationen erhalten Sie bei www.nea.com Takeda Ventures, Inc. (TVI) ist die Corporate Venture-Capital-Unternehmensgruppe der Takeda Pharmaceutical Company Limited (Takeda) und wurde 2001 mittels venturebasierten Partnerschaften mit Blick auf die Erzeugung von disruptiven Technologien und therapeutischen Lösungen für Patienten gegründet. Die Mission von TVI besteht darin, durch den Aufbau und die Verwaltung von sowie die Investition in innovationsbasierte Unternehmen strategische Wachstumsgelegenheiten für Takeda zu kreieren. TVI geht mit akademischen Innovatoren, Unternehmern und Venture-Investoren Partnerschaften ein, um ein Portfolio von Unternehmen in einer Vielfalt von therapeutischen Gebieten, darunter Onkologie, Gastroenterologie und Störungen des zentralen Nervensystems zu kreieren und zu nähren. Weitere Informationen erhalten Sie bei Das 1994 gegründete Unternehmen Pappas Capital tätigt seine Anlagen ausschließlich im Biowissenschaftensektor - Biotechnologie, Biopharmazeutika, Arzneimittelverabreichung, medizinische Gerätschaften und verwandte Ventures - in den Vereinigten Staaten und Kanada. Seit 2014 wurden drei von Pappas gegründete oder mitgegründete Portfolio-Unternehmen an große Pharmakonzerne verkauft: CoLucid Pharmaceuticals wurde im März 2017 von Eli Lilly für fast 1 Mrd. USD gekauft; Afferent Pharmaceuticals, wofür Merck 500 Mio. USD sofort zahlte und 750 Mio. USD in Meilensteinzahlungen; und Lumena Pharmaceuticals, die von Shire für über 300 Mio. USD gekauft wurde  Weitere Informationen erhalten Sie bei


News Article | May 24, 2017
Site: www.prnewswire.com

The capital will be used to advance the clinical development of OrphoMed's lead candidate, ORP-101, for the treatment of irritable bowel syndrome with diarrhea (IBS-D). ORP-101 is a metabolically stable, partial agonist of the μ opioid receptor and antagonist of the κ opioid receptor that is designed to mitigate both abdominal pain due to intestinal hyperalgesia and gastric hypermotility associated with IBS-D, without CNS penetration. In multiple clinically relevant animal models ORP-101 has consistently suppressed general and colon-specific hyperalgesic signals. Importantly, ORP-101 has been shown to not cause constriction of the sphincter of Oddi, which in turn could result in acute pancreatitis, as may occur with other μ agonists. ORP-101 is a proprietary molecule fully owned by OrphoMed, with no downstream royalties or milestone payments. Frank Torti, MD, Partner at NEA stated, "This is an exciting opportunity driven by a lead candidate with a proven mechanism of action, a large underserved patient population, and a results-oriented team with recent drug development success.  We are thrilled to partner with the OrphoMed team as they work to bring ORP-101 to patients in need." Nikhilesh Singh, PhD, OrphoMed cofounder and Chief Executive Officer, reiterated, "We are committed to developing drugs for gastrointestinal and hepatic conditions where there is a need for more efficacious and safer treatments.  We are excited by the investment from top-tier venture groups, as it validates the company's technology and strategy to pursue ORP-101, which has the potential to be a superior treatment alternative to existing therapies for IBS-D." Anthony Lembo, MD, Director of GI Motility and Functional Bowel Disorders Program at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School, believes that the pharmacological features of ORP-101 could position the molecule as a novel therapy for IBS-D, where there is an acute need for safe and efficacious treatments. "There are only a couple of drugs approved for the treatment of IBS-D, each with its own specific limitations, either regarding safety or efficacy," stated Kenneth Widder, MD, OrphoMed's Executive Chairman. "There still are a significant number of patients who cannot be treated with existing approved drugs. As such, we feel there is a large opportunity to bring forward a drug which circumvents the limitations of those drugs currently on the market." IBS-D is a multifactorial, symptom-based disorder marked by recurrent abdominal pain or discomfort and altered bowel function. It affects between 10 to 20 percent of people in the developed world, about one third of whom have IBS associated with diarrhea. IBS-D is more prevalent in women than men (14% vs. 9%).  About 57% of patients experience symptoms daily, 25% weekly and 14% monthly. The disease affects daily living, work and leisure. The cost of medical care for IBS patients is approximately 40% more than for the population in general. IBS patients account for approximately 20% of the secondary care burden of GI physicians' outpatient work.  The FDA has recently stated that there is a great medical need for new therapies for IBS. OrphoMed is a San Francisco Bay Area based clinical stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles.  The company is leveraging its proprietary dimer platform technology to address the issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders.  OrphoMed dimers are protected by composition of matter and method of use patents. OrphoMed is also exploring therapeutic applications and partnering opportunities for other dimer conjugates in its pipeline. For more information please visit New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With over $19 billion in cumulative committed capital since the firm's founding in 1977, NEA invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions. For additional information, visit www.nea.com Takeda Ventures, Inc. (TVI) is the corporate venture capital group of Takeda Pharmaceutical Company Limited (Takeda), and was founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based partnerships. TVI's mission is to create strategic growth opportunities for Takeda by building, managing and investing in innovation-based companies.  TVI partners with academic innovators, entrepreneurs and venture investors to create and nurture a portfolio of companies in an array of therapeutic areas, including oncology, gastroenterology and central nervous system disorders.  For additional information, please visit Founded in 1994, Pappas Capital invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada. Since 2014, three portfolio companies founded or co-founded by Pappas have been sold to large pharmaceutical companies: CoLucid Pharmaceuticals, bought in March 2017 by Eli Lilly for nearly $1 billion; Afferent Pharmaceuticals, for which Merck paid $500 million upfront and $750 million in milestones; and Lumena Pharmaceuticals, purchased by Shire for more than $300 million.  For additional information, visit To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orphomed-secures-39-million-series-a-financing-round-300462961.html


Patent
Afferent Pharmaceuticals | Date: 2015-07-02

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.


Patent
Afferent Pharmaceuticals | Date: 2017-05-10

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.


News Article | November 30, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Cough - Pipeline Review, H2 2016 addition with 38 market data tables and 12 figures, spread across 96 pages is available at http://www.reportsnreports.com/reports/703640-cough-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Ax-8, benzonatate, CCP-05, CCP-06, CCP-07, CCP-08, CLAT-313, codeine + guaifenesin, cromolyn sodium,         DWJ-1340, GRC-17536, GSK-2339345, guaifenesin + hydrocodone, guaifenesin ER , JNJ-39729209, lesogaberan, levodropropizine CR, MD-990, MK-7264, NEO-5937, orvepitant maleate, S-1226, Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders, Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases, ST-015, XEND-0501, Afferent Pharmaceuticals, Alitair Pharmaceuticals, Alveonix AG, AstraZeneca Plc, AusBio Ltd, Charleston Laboratories, Conrig Pharma ApS, Daewoong Pharmaceutical Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., GW Pharmaceuticals Plc, Hyundai Pharmaceutical Co., Johnson & Johnson, NeRRe Therapeutics Ltd, Orbis Biosciences Inc, Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=703640premium report price at US$2000 for a single user PDF license).


News Article | November 14, 2016
Site: www.prnewswire.co.uk

ReportsnReports.com adds "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Idiopathic Pulmonary Fibrosis with 78 market data tables and 15 figures, spread across 260 pages is available at http://www.reportsnreports.com/reports/743476-idiopathic-pulmonary-fibrosis-pipeline-review-h2-2016.html . Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants. Companies discussed in this Idiopathic Pulmonary Fibrosis Pipeline Review, H2 2016 report include AdAlta Pty Ltd., Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., Apellis Pharmaceuticals Inc, ARMO Biosciences, Inc., Asahi Kasei Pharma Corp., Biogen Inc, Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Celgene Corporation, Chrysalis Pharma SAS, Compugen Ltd., Cynata Therapeutics Limited, F. Hoffmann-La Roche Ltd., FibroGen, Inc., FibroStatin SL, Galapagos NV, GenKyoTex S.A., GlaxoSmithKline Plc, Global Blood Therapeutics, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Histocell S.L., iBio, Inc., Immunomet Therapeutics, Inc., Inventiva, Isarna Therapeutics GmbH, Kadmon Corporation, LLC, Kasiak Research Private Limited, Kolltan Pharmaceuticals, Inc., Kyorin Pharmaceutical Co., Ltd., Lung Therapeutics Inc, Moerae Matrix, Inc., MorphoSys AG, Novartis AG, Nuevolution AB, Pharmaxis Limited, Promedior, Inc., ProMetic Life Sciences Inc., Pulmatrix, Inc., Respira Therapeutics Inc, Ribomic Inc., Saje Pharma, LLC, Samumed LLC, Sanofi Sorrento Therapeutics, Inc., SPR Biosciences LLC, Teva Pharmaceutical Industries Ltd., Therabron Therapeutics, Inc., Vicore Pharma AB and Yuhan Corporation. The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Another newly published market research report titled Bronchiectasis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Alitair Pharmaceuticals, Inc., Bayer AG, Grifols, S.A., Insmed Incorporated, Kamada Ltd., Polyphor Ltd., Raptor Pharmaceutical Corp., Recipharm AB, Savara Inc. and Vertex Pharmaceuticals Incorporated. Bronchiectasis Pipeline market research report of 84 pages is available at http://www.reportsnreports.com/reports/743455-bronchiectasis-pipeline-review-h2-2016.html . ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:


ReportsnReports.com adds "Postherpetic Neuralgia - Pipeline Review, H2 2016" to its store providing an overview of the Postherpetic Neuralgia's therapeutic pipeline with comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. Complete report on H2 2016 pipeline review of Postherpetic Neuralgia with 32 market data tables and 15 figures, spread across 98 pages is available at http://www.reportsnreports.com/reports/729116-postherpetic-neuralgia-pipeline-review-h2-2016.html. Postherpetic neuralgia is a complication of shingles, which is caused by the chickenpox (herpes zoster) virus. Signs and symptoms may include pain, sensitivity to light touch, itching and numbness and weakness or paralysis. The predisposing factors include age, people with HIV and Hodgkin's lymphoma. Treatment includes anticonvulsants, antidepressants and opioid painkillers. Postherpetic Neuralgia pipeline therapeutics constitutes close to 23 molecules. which approximately 23 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 3, 7 and 1 respectively. The report outlays comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies discussed in this Postherpetic Neuralgia Pipeline Review, H2 2016 report include Aestus Therapeutics, Inc., ContraVir Pharmaceuticals, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Immune Pharmaceuticals Inc., Jiangsu Hengrui Medicine Co., Ltd., KPI Therapeutics, Inc., Lpath, Inc., Merck & Co., Inc., Patagonia Pharmaceuticals, LLC, Pfizer Inc., Phosphagenics Limited, Relmada Therapeutics, Inc., Scilex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. and Toray Industries, Inc. Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=729116. Drug Profiles mentioned in this research report are (amitriptyline + ketamine hydrochloride), (clonidine hydrochloride + naltrexone hydrochloride), ATX-08001, bupivacaine hydrochloride, C-746, DWP-05195, funapide, FV-100, ketoprofen, lidocaine hydrochloride, lidocaine hydrochloride patch, Lpathomab, mepivacaine hydrochloride, mirogabalin besylate, MK-8291, naltrexone hydrochloride, PATN-02, pregabalin CR, pregabalin SR, REL-1017, TRK-700, U-2902 and zucapsaicin. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Another newly published market research report titled on Pulmonary Fibrosis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are AdAlta Pty Ltd., Advinus Therapeutics Ltd, Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Asahi Kasei Pharma Corp., aTyr Pharma, Inc., Biogen Inc, Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Celgene Corporation, Chrysalis Pharma SAS, Clanotech AB, Compugen Ltd., Cynata Therapeutics Limited, Diffusion Pharmaceuticals Inc., Digna Biotech, S.L., Elsalys Biotech SAS, F. Hoffmann-La Roche Ltd., FibroGen, Inc., FibroStatin SL, Galapagos NV, Galectin Therapeutics, Inc., GenKyoTex S.A., GlaxoSmithKline Plc, Global Blood Therapeutics, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Yuhan Corporation etc. Pulmonary Fibrosis Pipeline market research report of 377 pages is available at http://www.reportsnreports.com/reports/729115-pulmonary-fibrosis-pipeline-review-h2-2016.html. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:


Ford A.P.,Afferent Pharmaceuticals
Purinergic Signalling | Year: 2012

Treating pain by inhibiting ATP activation of P2X3-containing receptors heralds an exciting new approach to pain management, and Afferent's program marks the vanguard in a new class of drugs poised to explore this approach to meet the significant unmet needs in pain management. P2X3 receptor subunits are expressed predominately and selectively in so-called C- and Aδ-fiber primary afferent neurons in most tissues and organ systems, including skin, joints, and hollow organs, suggesting a high degree of specificity to the pain sensing system in the human body. P2X3 antagonists block the activation of these fibers by ATP and stand to offer an alternative approach to the management of pain and discomfort. In addition, P2X3 is expressed pre-synaptically at central terminals of C-fiber afferent neurons, where ATP further sensitizes transmission of painful signals. As a result of the selectivity of the expression of P2X3, there is a lower likelihood of adverse effects in the brain, gastrointestinal, or cardiovascular tissues, effects which remain limiting factors for many existing pain therapeutics. In the periphery, ATP (the factor that triggers P2X3 receptor activation) can be released from various cells as a result of tissue inflammation, injury or stress, as well as visceral organ distension, and stimulate these local nociceptors. The P2X3 receptor rationale has aroused a formidable level of investigation producing many reports that clarify the potential role of ATP as a pain mediator, in chronic sensitized states in particular, and has piqued the interest of pharmaceutical companies. P2X receptor-mediated afferent activation has been implicated in inflammatory, visceral, and neuropathic pain states, as well as in airways hyperreactivity, migraine, itch, and cancer pain. It is well appreciated that oftentimes new mechanisms translate poorly from models into clinical efficacy and effectiveness; however, the breadth of activity seen from P2X3 inhibition in models offers a realistic chance that this novel mechanism to inhibit afferent nerve sensitization may find its place in the sun and bring some merciful relief to the torment of persistent discomfort and pain. The development philosophy at Afferent is to conduct proof of concept patient studies and best identify target patient groups that may benefit from this new intervention. © 2011 The Author(s).


Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R^(1 )and R^(2 )are as defined herein.


Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R^(1 )and R^(2 )are as defined herein.

Loading Afferent Pharmaceuticals collaborators
Loading Afferent Pharmaceuticals collaborators